VJOncology Podcast

Key Updates from ESMO Breast 2024

In today's episode, we bring you key highlights from ESMO Breast 2024, diving into important discussions surrounding the latest research and clinical data regarding breast cancer. We bring insights from top field experts, set to enlighten you on new breakthroughs and developments, including updates from the DESTINY-Breast02 trial as well as first-line CDK4/6 inhibitor clinical data in HR+/HER2-advanced breast cancer. 

Bladder Cancer Awareness Month Part II: Management of UC in the UK

In this podcast, we continue to commemorate Bladder Cancer Awareness Month in
May with a special limited series, where we invite a special guest to
discuss and share their expert perspectives within this ever evolving field.
This week, Rob Jones, MD, PhD, University of Glasgow, Glasgow, UK, will be talking about first-line treatment paradigms in bladder cancer, survivorship challenges, and the current state of bladder cancer treatment in the UK. 

Bladder Cancer Awareness Month Part I: The past, present, and future of ADCs

In this podcast, we commemorate Bladder Cancer Awareness Month in
May with a special limited series, where we invite a special guest to
discuss and share their expert perspectives within this ever evolving field.
This week, Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer
Center, New York, NY, will be talking about antibody-drug conjugates,
which have made a big impact in the treatment landscape of bladder
cancer and other solid tumors. He will provide his thoughts on the
approval of enfortumab vedotin, managing toxicities, and the future of
ADCs

BTOG 2024 Highlights

Join us for an enlightening podcast hosted by VJOncology, featuring a panel of renowned experts sharing the latest advancements in lung cancer research from BTOG 2024. 

In the first segment, listeners are offered a deep dive into the early stages of lung cancer as Charles Swanton (Francis Crick Institute, London, UK) examines the correlation between air pollution exposure and cancer development. Following this, Thomas Newsom-Davies (Chelsea and Westminster Hospital NHS Foundation Trust, London, UK) provides insight into some of the exciting progress taking place in TNM staging, systematic staging, and immunotherapy. Mariana Brandao (Institute Jules Bordet, Brussels, Belgium) steers the discussion to the complex task of determining operability in non-small cell lung cancer. She emphasizes the importance of a comprehensive operability assessment, highlighting the challenges associated with the disease's complex heterogeneity, particularly in stage three patients.

Winding down the session, Robert Rintau (University of Cambridge & Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK,) weighs in on the implications of increased lung cancer survival rates and the evolving approach to treatment. 

The podcast rounds off with reflections from Crispin Hiley (UCL, London, UK) on the HIT-Meso trial from and Sanjay Popat (The Royal Marsden NHS Foundation Trust, London, UK) reflects on the success of BTOG 2024 emphasizing the comprehensive representation of multidisciplinary teams dedicated to managing primary thoracic malignancies. Listen now to gain valuable insights into the rapidly evolving landscape of lung cancer treatment and research.

Highlights from AACR 2024: KRYSTAL-1, FLAURA2, and EDGE

This week, we cover key updates from the American Association for Cancer Research (AACR) 2024 Annual Meeting, held in San Diego, CA. Hear from Scott Koptez, The University of Texas MD Anderson Cancer Center, Houston, TX, Rebecca Porter, Dana-Farber Cancer Institute, Boston, MA, Pasi Janne, Dana-Farber Cancer Institute, Boston, MA, and Elizabeth Swisher, Fred Hutchinson Cancer Center, Seattle, CA, as they discuss takeaways from the meeting.

Updates in immunotherapy for head and neck cancer

In this podcast, we highlight some of the latest updates in the use of immunotherapy to treat head and neck cancer. This week we will be joined by Nicolas Mach, MD, Hôpitaux Universitaires de Genève, Geneva, Switzerland; Emrullah Yilmaz, MD, PhD, Cleveland Clinic, Cleveland, OH; Emrullah Yilmaz, MD, PhD, Cleveland Clinic, Cleveland, OH; Ari Rosenberg, MD, University of Chicago, Chicago, IL and Nabil Saba, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA.

We will hear about the results of the SAKK 11/16 trial (NCT02999646) of the MVX-ONCO-1 vaccine, a Phase I dose expansion trial (NCT04429542) of BCA101, a bifunctional EGFR/TGFβ inhibitor, with pembrolizumab, and increasing T-cell responses in HPV-positive head and neck cancer with TheraT vectors, as well as other novel immunotherapy approaches.

For other head and neck cancer news, head over to our Head and Neck Cancer Channel.

Subscribe to our podcasts on Apple Podcasts, Podbean, and Spotify and join the conversation via X (formerly Twitter) @VJOncology. For more updates in the field, visit vjoncology.com.

Updates in immunotherapy for skin cancer

In this podcast, we highlight some of the latest updates in the use of immunotherapy to treat skin cancer. This week, we will be joined by Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA; Paolo Ascierto, MD, Istituto Tumori Fondazione Pascale, Naples, Italy; Georgina Long, PhD, MBBS, FRACP, FAHMS, The University of Sydney, North Sydney, Australia; and Karijn Suijkerbuijk, MD, PhD, UMC Utrecht, Utrecht, The Netherlands. 

 

We will hear on the impact of T-Cell therapies, such as lifileucel, in patients with melanoma; results of the 7-year CheckMate 238 trial (NCT02388906) of nivolumab; effective sequencing of treatments in the SECOMBIT trial (NCT02631447); and challenges in managing immunotherapy related adverse events.

 

If you would like to learn more about the recent approval of lifileucel by the FDA, you can find our feature article here. For other skin cancer news, be sure to visit our dedicated Skin Cancer Channel.

 

Subscribe to our podcasts on Apple Podcasts, Podbean, and Spotify and join the conversation via X (formerly Twitter) @VJOncology. For more updates in the field, visit vjoncology.com.

Highlights in colorectal cancer at ASCO GI 2024

In this week's podcast by VJ Oncology, six leading experts share their insights on cutting-edge developments in colorectal cancer screening and treatment, drawn from highlights of the 2024 ASCO Gastrointestinal (GI) Cancers Symposium held in San Francisco, CA. One key focus was the rapid evolution of non-invasive blood-based tests for colorectal cancer screening, as discussed by Aasma Shauka from New York University. Further, Theodore R. Levin from Kaiser Permanente shared the effectiveness of stool-based testing in achieving high adherence rates for colorectal cancer screening. Meanwhile, Sebastian Stintzing from Charité – Universitätsmedizin Berlin analyzed the Phase II FRASCO2 trial, demonstrating the benefit of fruquintinib for heavily pre-treated patients with refractory metastatic colorectal cancer in a Q-TWIST analysis. Edward Esplin from Invitae speaks on the potential of personalized monitoring tests in early-stage colorectal cancer treatment and Van K. Morris from the University of Texas analyzing a prospective phase 2 clinical trial for previously treated metastatic colorectal cancer. Finally, Anwar Saeed's discusses the rationale behind STELLAR-303 trial aiming to address unmet needs of patients with specific types of metastatic colorectal cancer.

Targeted therapies for lung cancer at TTLC 2024

This week, we cover interesting research from TTLC 2024, focusing on innovative treatments for lung cancer. Starting off, Bruna Pellini from Moffitt Cancer Center, FL, talks about the utility of circulating tumor DNA as a biomarker of progression in lung cancer, her latest findings from notable Phase III trials and ongoing studies looking into increasing treatment based on this biomarker.

 

Next, Monica Chen from Memorial Sloan Kettering Cancer Center, NY, discusses the role of osimertinib with chemotherapy as initial treatment for patients with metastatic EGFR mutant lung cancers with concurrent TP53 and RB1 alterations from a clinical trial perspective.

 

Our final speaker, Timothy Burns from University of Pittsburgh, PA, shares detailed insights into non-TKI treatment options for EGFR mutant lung cancer. He discusses the exciting prospects of upcoming studies, potential FDA approvals and the integrated role of immuno-modulatory agents in EGFR mutant patients.

 

Our podcast aims to deliver the latest and most intriguing updates in the field directly to you. Follow us on Twitter at @vjoncology and visit our website for the newest trends.

Updates in invasive lobular carcinoma (ILC)

Invasive lobular carcinoma (ILC) poses unique challenges in breast cancer management. Its subtle presentation and distinct biological behavior demand a nuanced approach from healthcare professionals. In this podcast, we delve into the epidemiology, pathology, diagnostic methods, treatment modalities, and emerging research surrounding ILC. By comprehensively understanding this subtype, healthcare professionals can optimize patient care and ultimately improve patient outcomes. In this enlightening podcast from VJ Oncology, join our distinguished guests, Jason Aboudi Mouabbi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Fresia Pareja, MD, Memorial Sloan Kettering Cancer Center, New York, NY, as they delve into the complexities of ILC.